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Abstract
Background Chronic stable angina negatively affects
quality of life (QoL). American College of Cardiology/
American Heart Association guidelines highlight main-
taining/restoring a level of activity, functional capacity,
and QoL that is satisfactory to the patient as an objective of
treatment, and further define the treatment goal for most
patients as maximizing survival and achieving prompt and
complete (or near-complete) elimination of angina with a
return to normal activities.
Objective To assess self-reported angina severity, fre-
quency, and QoL in patients with chronic stable angina
who had not undergone revascularization and who were
prescribed and remained on ranolazine.
Methods Patients (N = 92) answered a survey evaluating
their perceptions of angina prior to ranolazine initiation
(based on recall of previous experience) and during ra-
nolazine treatment. Change in QoL was assessed using the
Patient Global Impression of Change scale.
Results Most respondents were female (64 %) and had
taken ranolazine for C6 months (89 %); mean age was
64 years. The majority of respondents selected higher
scores for angina severity before ranolazine treatment
(54 %), and lower scores for severity while on ranolazine
(68 %). Most respondents reported experiencing C1 angina
attack/week before ranolazine treatment (82 %) and \1
attack/week while on ranolazine (73 %). The effect of
angina on daily activities was less while taking ranolazine
than before ranolazine treatment; 52 and 8 % of respon-
dents, respectively, reported significant impact, and 12 and
67 %, respectively, reported little/no impact. Most
respondents reported noticeably improved angina-related
QoL since starting ranolazine (79 %).
Conclusion Patients who maintained ranolazine treatment
for durations ranging from\6 months to[4 years reported
substantial improvements in angina severity, frequency,
and QoL.
1 Introduction
Coronary heart disease (CHD) is the most common form of
heart disease in the United States (US), affecting an esti-
mated 15.4 million adults aged C20 years (6.4 %) [1]. In
2009, almost 400,000 deaths were attributed to CHD, and
each year approximately 635,000 individuals will have a
primary coronary attack. An estimated 7.8 million adults
aged C20 years (3.2 %) in the US experience angina
pectoris, a recurrent and debilitating chest pain, which is an
underlying symptom of CHD [1]. Chronic stable angina is
diagnosed in approximately 500,000 individuals aged
C45 years annually, and is a negative predictor of quality
of life (QoL) in many patients with CHD [1–3]. Angina
places a high burden on the US healthcare system, with
direct healthcare costs associated with the disease esti-
mated to range from US$1.9 to US$75 billion, depending
on the definition of angina used [4].
In patients with chronic stable angina, the occurrence of
C1 episode of angina on a weekly basis is associated with
worse QoL and greater physical limitations [5]. Recent
American College of Cardiology (ACC)/American Heart
Association (AHA) guidelines for the management of stable
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ischemic heart disease highlight maintaining or restoring a
level of activity, functional capacity, and QoL that is satis-
factory to the patient as one of the objectives of treatment for
this patient population. The guidelines define the goal of
treatment for most patients as maximizing survival and
achieving prompt and complete (or near-complete) elimi-
nation of angina with a return to normal activities [6].
Traditional therapies for chronic stable angina include
b-blockers, calcium channel blockers, and long-acting
nitrates [6]. For some patients, use of these agents may be
limited by key adverse effects of b-blockers (bradycardia,
heart block, hypotension, bronchospasm) and calcium
channel blockers (ankle edema, headache, flushing, hypo-
tension), as well as tolerance associated with long-term use
of nitrates [7].
The sodium channel inhibitor ranolazine is indicated to
treat chronic stable angina and may be used with b-
blockers, calcium channel blockers, and nitrates [8]. When
taken in combination with standard doses of b-blockers or
calcium channel blockers, ranolazine improved exercise
duration and time to ischemia, and reduced the frequency
of angina attacks and nitroglycerin use in patients with
severe chronic angina [9].
In a pilot study comparing ranolazine and placebo for
4 weeks each in a crossover fashion in 20 women with
angina and evidence of myocardial ischemia but no
obstructive coronary artery disease, scores were signifi-
cantly better for ranolazine on the Seattle Angina Ques-
tionnaire (SAQ) subscales assessing physical functioning
(91.7 vs. 83.3; p = 0.046), angina stability (75.0 vs. 50.0;
p = 0.008), and QoL (75.0 vs. 66.7; p = 0.021) [10]. A
prospective QoL assessment performed alongside the
MERLIN (Metabolic Efficiency with Ranolazine for Less
Ischemia in Non–ST-elevation acute coronary syndromes)-
TIMI 36 trial showed small but statistically significant
effects of ranolazine on disease-specific health status and
QoL over 12 months’ follow-up [11].
Little is known regarding the impact of ranolazine on QoL
over longer treatment durations. The present patient survey
was designed to evaluate the effect of long-term (up to
[4 years) ranolazine treatment on self-reported angina
severity, frequency, and QoL in patients with chronic angina.
2 Methods
A 40-question survey was distributed from 6 April to 10 May
2011, via email and telephone, to a panel of patients currently
receiving ranolazine treatment. Patients were invited to
participate in the panel through website registration (Ra-
nexa.com and SpeakFromTheHeart.com), by opting-in for
research, or via savings program participation. Patients
answered screening questions (for which they received
honoraria) in order to join the panel; the screening criteria
included age C18 years; being on ranolazine treatment
prescribed by a healthcare professional (not including use of
only a sample); and no employment of themselves or any
immediate family member by a pharmaceutical manufac-
turer, medical equipment manufacturer, market research or
advertising firm, medical office, clinic, or hospital. Panel
members were subsequently invited and opted to participate
in the survey.
The survey assessed patients’ perceptions of their angina
severity and frequency, impact on daily activities, and QoL
before initiating ranolazine treatment (based on patient-
reported recall of their previous experience), and at the
time of the survey while on ranolazine. Angina severity
was rated using a 7-point Likert scale (where 1 = extremely
mild and 7 = extremely severe). Respondents classi-
fied the frequency of angina attacks as: more than once per
day; about once per day; less than once a day, but one or
more per week; or less than once a week. The impact of
angina on patients’ daily activities was also rated using a
7-point Likert scale (where 1 = not at all and 7 = a lot).
Change in QoL was assessed using the Patient Global
Impression of Change (PGIC) scale [12]. Respondents
classified changes in activity limitations, symptoms, emo-
tions, and overall QoL related to angina as one of the
following categories:
• no change (or condition has got worse);
• almost the same, hardly any change at all;
• a little better, but no noticeable change;
• somewhat better, but the change has not made any real
difference;
• moderately better, and a slight but noticeable change;
• better, and a definite improvement that has made a real
and worthwhile difference;
• a great deal better, and a considerable improvement that
has made all the difference.
In addition, the degree of change experienced was rated
using an 11-point Likert scale (where 0 = much better,
5 = no change, and 10 = much worse).
The analysis was limited to respondents who had not
undergone revascularization procedures (coronary artery
bypass graft or percutaneous coronary intervention [PCI]) to
provide a more clear assessment of the effects of ranolazine
therapy. Results are presented as percentage of patients.
3 Results
3.1 Survey Participant Demographics
The survey was distributed to all panel members (n = 741;
all patients on the panel met the pre-specified screening
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criteria), and 399 patients (54 %) completed the survey.
The results from 92 panel members who answered the
survey and had not undergone revascularization are pre-
sented herein. The majority (59 %) completed the survey
by phone, the rest via email. Table 1 summarizes the
baseline characteristics of the population, their comorbid
cardiovascular conditions, and any additional anti-angina
medications used at the time of the survey. The majority of
respondents were female (64 %), and the mean age was
64 years. At the time of the survey, approximately half of
the respondents had been diagnosed with angina for
C2 years (52 %), and most respondents had been taking
ranolazine for C6 months (89 %). Almost 90 % of patients
surveyed had a cardiovascular condition in addition to
angina, and approximately three-quarters of the population
received ranolazine therapy plus an additional anti-angina
medication.
3.2 Angina Severity and Frequency
Angina severity before ranolazine treatment was scored as
6 or 7 by 54.4 % of respondents and as 1 or 2 by only
5.4 % of respondents; severity ratings after ranolazine were
6 or 7 in 2.2 % of respondents and 1 or 2 in 68.5 % of
respondents (Fig. 1).
The proportion of respondents reporting angina fre-
quencies of \1 attack per day but C1 attack per week,
about 1 attack per day, and [1 attack per day were lower
after ranolazine therapy than before ranolazine, while the
proportion reporting the least frequent category of \1
attack per week was higher after ranolazine (Fig. 2).
3.3 Impact of Angina on Daily Activities and Quality
of Life
When respondents were asked to rate the impact of angina
on their daily activities, 52.1 % of respondents reported
that angina had a significant impact on their daily activities
(score of 6 or 7) before treatment with ranolazine; only
7.6 % of respondents reported a significant impact after
ranolazine (Fig. 3). The proportion of respondents report-
ing little/no impact of angina on daily activities (score of 1
or 2) increased from 11.9 % before ranolazine to 67.4 %
after ranolazine.
As assessed by the PGIC scale, a majority of respondents
(79.4 %) reported a noticeable improvement (moderately
better, better, or a great deal better) in QoL since initiating
ranolazine therapy (Fig. 4). The degree of change in QoL
revealed that 89.1 % of patients reported a score of \5.
4 Discussion
In this patient survey, respondents with chronic angina who
did not have a history of revascularization reported substantial
improvement in QoL, angina frequency, and angina severity
after initiating therapy with ranolazine. These improvements
represent key treatment goals established by ACC/AHA
guidelines for patients with chronic stable angina.
Chronic stable angina can have a significant negative
impact on daily activities and QoL of patients with CHD
[13]. Invasive procedures such as PCI, coronary artery
bypass grafting, and stenting have been shown to improve






Age, years, mean (range) 64 (35–90)
Age at angina diagnosis, years, mean (range) 58 (20–88)
Monthly angina attacks, n (range) 7 (0–60)
Duration of ranolazine treatment, n (%)
\6 months 10 (11)
6–12 months 37 (40)
[1 to B2 years 29 (32)
[2 to B4 years 14 (15)
[4 years 2 (2)
Time since angina diagnosis, n (%)
\2 years 44 (48)
C2 to \4 years 19 (21)
C4 to \6 years 6 (7)
C6 to \8 years 7 (8)
C8 to \10 years 3 (3)
C10 years 13 (14)
Comorbid CV conditions, n (%)
Any comorbid conditiona 82 (89)
Atrial fibrillation 17 (18)
Congestive heart failure 27 (29)
Diabetes mellitus 33 (36)
High blood pressure/hypertension 65 (71)
Anti-anginal medications, n (%)







a Includes atrial fibrillation, congestive heart failure, and high blood
pressure/hypertension
b In addition to ranolazine; includes atorvastatin, warfarin, digoxin,
clonazepam, and nitroglycerin
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QoL in patients with severe angina [14, 15]. However,
many patients with stable ischemic heart disease may
benefit from medical therapy [16]. Interestingly, among
patients with stable angina in the RITA-2 (Second Ran-
domized Intervention Treatment of Angina) and COUR-
AGE (Clinical Outcomes Utilizing Revascularization and
Aggressive druG Evaluations) trials, early superiority of
PCI over medical therapy in improving QoL had attenuated
by 3 years, although this observation may be attributable in
part to patients assigned to medical therapy subsequently
undergoing invasive treatment [15, 17]. In COURAGE,
patients with more severe and more frequent angina were
found to gain the greatest benefit from PCI [15].
Ranolazine can be used as initial anti-anginal therapy
(particularly in situations where there is a contraindication
to traditional anti-angina medications, or a concern about
decreases in blood pressure or heart rate), or as add-on
therapy to nitrates, b-blockers and calcium channel
blockers [18]. Currently, ranolazine is indicated for
patients with chronic stable angina, not for patients with
Fig. 1 Patient-reported angina
severity before and after taking
ranolazine. N = 92 respondents.
Angina severity was rated using
a 7-point Likert scale (where
1 = extremely mild and
7 = extremely severe)
Fig. 2 Patient-reported
frequency of angina attacks
before and after taking
ranolazine. N = 92 respondents
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stable ischemic heart disease. However, some suggest that
there is a need for ranolazine in the broader CHD popu-
lation, such as in those with cardiac X syndrome, who often
have no response to conventional anti-anginal therapy, or
those with ischemic heart disease plus diabetes mellitus or
arrthymias [19, 20]. While the high cost of ranolazine
versus other anti-angina medications often leads to physi-
cians opting to use ranolazine as a second-line or later
treatment [18], the use of ranolazine in patients with poorly
controlled angina is associated with decreases in
revascularization rates, prescription costs, and a reduction
in total care costs compared with patients receiving
nitrates, b-blockers or calcium channel blockers [21]. Thus,
the use of ranolazine can reduce the large financial burden
chronic stable angina puts on the healthcare system.
The improvements in QoL and severity of angina attacks
reported by respondents on ranolazine in the present survey
reflect the efficacy of outcomes tools such as the SAQ used
to assess QoL in patients with chronic stable angina [13].
The trend in improved QoL reported by respondents taking
Fig. 3 Patient-reported impact
of angina on daily activities
before and after taking
ranolazine. N = 92 respondents.
The impact of angina on daily
activities was rated using a
7-point Likert scale (where
1 = not at all and 7 = a lot)
Fig. 4 Patient-reported changes
in quality of life on the Patient
Global Impression of Change
scale since initiating ranolazine
treatment. N = 92 respondents
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ranolazine in this survey mirror similar trends reported in
randomized clinical trials in which ranolazine therapy was
reported to improve angina and QoL scores in patients with
acute coronary syndromes who had a history of chronic
angina. Post-hoc analysis of QoL data from MERLIN-
TIMI 36 indicated that the benefit of ranolazine was most
apparent in the subgroup of patients with a history of prior
angina (approximately 54 % of the entire MERLIN popu-
lation). Among these patients, significant effects versus
placebo were seen on most domains assessed, with the
greatest mean treatment effects observed for the SAQ
assessments of angina frequency (mean treatment effect 3.4
points; p \ 0.001), QoL (2.7 points; p \ 0.001), and
treatment satisfaction (1.5 points; p = 0.004) [11]. In
addition, the results of a study in women with angina and
myocardial ischemia showed that treatment with ranolazine
produced significantly better median SAQ scores for
physical functioning, angina stability, and QoL than pla-
cebo [10], and a study in a group of veterans with chronic
stable angina who received ranolazine in addition to opti-
mal doses of conventional therapy demonstrated clinically
significant improvements from baseline in SAQ scores in
the domains of physical limitation, angina stability, and
disease perception after 1 and 3 months of treatment [22].
The survey results may also reflect the good tolerability of
ranolazine in the appropriate patient subset when used over
an extended duration (up to 4 years).
The present study has some limitations that should be
considered when drawing conclusions. A control group was
not established for comparative purposes, as only patients
receiving ranolazine were recruited to participate. Never-
theless, as coronary artery disease is a gradually progres-
sive disease, improvement from pretreatment values (while
on background therapy) suggests a beneficial role for ra-
nolazine. We could not account for confounding factors,
and no information on the CHD profiles of the patients (i.e.,
the presence of obstructive/non-obstructive disease or
normal arteries) was collected. The survey participants
comprise a select group of respondents who were taking
ranolazine and filling ranolazine prescriptions over time.
Presumably, patients who did not respond to ranolazine
would not have continued their participation in the panel;
the proportion of patients who terminated ranolazine
treatment and their reasons for doing so (e.g., efficacy,
tolerability, expense) are unknown, although placebo-con-
trolled study data give an indication of the proportion of
patients who are anticipated to respond to ranolazine [23].
Given that only 54 % of the total panel completed the
survey, it is possible that some bias was introduced,
because of potential differences between those who
answered the survey and those who did not; however,
patients were not pre-selected for a positive response to
ranolazine, and in our experience, patients with a negative
therapy experience are much more likely to respond to a
survey than those with a positive experience, and thus we
consider our results to be valid. While the accuracy of
symptom recall over a relatively long period of time
(6 months to 4 years) is a potential concern, the angina-
related impact on QoL was such that most patients felt
comfortable assessing their symptoms; those who could not
accurately recall or assess their symptoms were not
recruited to the study. In addition, there was no difference
in the results between those with 6 months’ experience and
those with 4 years’ worth, which suggests that patient
recall was reliable in this case. It should also be noted the
use of the PGIC scale versus other validated scales for
angina severity and QoL is an additional limitation; how-
ever, the SAQ was not included in this survey due to
limitations associated with its length.
5 Conclusion
Patients with chronic angina maintaining treatment with
ranolazine over time, with treatment durations ranging from
\6 months to [4 years, reported substantial reductions in
the severity and frequency of angina attacks, reductions in
the impact of angina on daily activities, and improvements
in QoL. These observations correspond to key treatment
goals established by ACC/AHA guidelines for patients
with stable ischemic heart disease.
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